Touchstone
Last syncNov 1, 2026, 6:55 PM ET

INDV

Indivior Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$35.37Close $4.4BMarket cap $28.78 – $41.8352-week range Jan 30, 2027Next report · estimated

Highlights

Strengths

  • Earnings growing EPS +245% year on year

Cautions

  • Not in an uptrend 3 of 8 trend conditions

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 29, 2026
Off 12-month high 15%
1wk up 2.6% price change
1mo down 1.3% price change
12-month return up 21% market up 11% · its own up 29%
F-score 4 / 9 Weak
Altman Z 3.25 Low risk
P/E 21.1× price / earnings
PEG 0.01 P/E / EPS growth
P/B — price / book
Earnings yield up 5.8% EBIT / enterprise value
Cheaper than 46% of the market · around average
Revenue growth up 4% year on year
EPS growth up 245% latest quarter · -344 pts
Sales growth up 13% latest quarter · -0 pts
ROE — return on equity
Free cash margin down 8% -$93.0M FCF
D/E — long-term debt / equity
Net debt / EBITDA 0.3×
Interest cover 6.9×EBIT / interest
Piotroski tests
  • operating cash flow is negative
  • profits not fully backed by cash
  • took on more long-term debt
  • short-term liquidity weakened
  • gross margin narrowed
  • profitable on its assets
  • profitability improving
  • no new shares issued
  • assets working harder

Repair signals

  • Long-term debt down 8% ($0.3B → $0.3B)

Trade setup

ATR% 3.5% $1.23 a day · 2×ATR $32.92
RS 52 / 99 vs the universe
Trend 3 / 8 trend template
Relative volume 2.0× vs 50-day average
Up/down volume 1.11 50 sessions
Implied move — no scheduled report
Trend template · 3 of 8
  • Price above the 150 and 200-day averages: fails
  • 150-day average above the 200-day: passes
  • 200-day average rising for a month: fails
  • 50-day average above the 150 and 200-day: fails
  • Price above the 50-day average: passes
  • At least 30% above the 52-week low: fails
  • Within 25% of the 52-week high: passes
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

2 flagged
  • Liabilities exceed assets Shareholders' equity is negative at -$98.0M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
  • Profit not backed by cash Reported profit of $210.0M came with -$27.0M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported Oct 29, 2026
Results reaction Oct 29, 2026+4% vs market2 sessions after results

Financials

4 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $1.2B +4% on FY2024
$0 $2B FY22 FY23 FY24 FY25 FY2022 · $901.0M FY2023 · $1.1B FY2024 · $1.2B FY2025 · $1.2B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $210.0M +2900% on FY2024
-$200M $0 $250M FY22 FY23 FY24 FY25 FY2022 · -$42.0M FY2023 · -$126.0M FY2024 · $7.0M FY2025 · $210.0M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$93.0M down to a loss
-$500M $0 FY22 FY23 FY24 FY25 FY2022 · -$9.0M FY2023 · -$308.0M FY2024 · $7.0M FY2025 · -$93.0M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 80%
  • Net 17%
  • Free cash -8%
-50% 0% 100% FY22 FY23 FY24 FY25 FY2022 · Gross 83% · Net -5% · Free cash -1% FY2023 · Gross 84% · Net -12% · Free cash -28% FY2024 · Gross 81% · Net 1% · Free cash 1% FY2025 · Gross 80% · Net 17% · Free cash -8%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $95.0M net debt
  • Cash
  • Long-term debt
$0 $1B FY22 FY23 FY24 FY25 FY2022 · Cash $774.0M FY2023 · Cash $316.0M · Long-term debt $237.0M FY2024 · Cash $319.0M · Long-term debt $315.0M FY2025 · Cash $195.0M · Long-term debt $290.0M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 125m -8.1% since FY2022
136.53m 125m FY22 FY23 FY24 FY25 FY2022 · 136m FY2023 · 136.53m FY2024 · 125m FY2025 · 125m
  FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $901.0M $1.1B $1.2B $1.2B
Gross margin 83% 84% 81% 80%
Operating income -$77.0M -$152.0M $38.0M $262.0M
Net income -$42.0M -$126.0M $7.0M $210.0M
Net margin -5% -12% 1% 17%
Earnings per share -$0.30 -$0.92 $0.05 $1.64
Free cash flow -$9.0M -$308.0M $7.0M -$93.0M
Free cash margin -1% -28% 1% -8%
Cash $774.0M $316.0M $319.0M $195.0M
Long-term debt — $237.0M $315.0M $290.0M
Shareholders' equity -$15.0M -$184.0M -$337.0M -$98.0M
Shares outstanding 136m 136.53m 125m 125m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Oct 29, 2026 Quarterly ↗ Sep 30, 2026 29d
Aug 3, 2026 Quarterly ↗ Jun 30, 2026 34d
Apr 30, 2026 Quarterly ↗ Mar 31, 2026 30d
Feb 26, 2026 Annual ↗ Dec 31, 2025 57d
Oct 30, 2025 Quarterly ↗ Sep 30, 2025 30d
Jul 31, 2025 Quarterly ↗ Jun 30, 2025 31d
May 1, 2025 Quarterly ↗ Mar 31, 2025 31d
Mar 3, 2025 Annual ↗ Dec 31, 2024 62d
Mar 6, 2024 Annual ↗ — 0d

Current reports

FiledDisclosed
Oct 29, 2026 Results ↗
Oct 15, 2026 Shareholder vote ↗
Oct 6, 2026 Other events ↗
Sep 17, 2026 Regulation FD · Other events ↗
Sep 15, 2026 Agreement ended ↗
Aug 3, 2026 Regulation FD ↗
Aug 3, 2026 Results · Regulation FD ↗
Aug 3, 2026 Material agreement · Regulation FD ↗
May 15, 2026 Director or officer change · Shareholder vote ↗
May 4, 2026 Regulation FD · Other events ↗
Apr 30, 2026 Results · Regulation FD ↗
Mar 17, 2026 Material agreement · Agreement ended · New obligation · Unregistered share sale ↗